The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation
Open accessAbstract
OBJECTIVES: To examine the clinical effectiveness, tolerability and cost-effectiveness of gabapentin (GBP), lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine (OXC), tiagabine (TGB), topiramate (TPM) and vigabatrin (VGB) for epilepsy in adults. DATA SOURCES: Electronic databases. Internet resources. Pharmaceutical company submissions. REVIEW METHODS: Selected studies were screened and quality assessed. Separate analyses assessed clinical effectiveness, serious, rare and long-term adverse events and cost-effectiveness. An integrated economic analysis incorporating information on costs and effects of newer and older antiepileptic drugs (AEDs) was performed to give direct comparisons of long-term costs and benefits. RESULTS: A total of 212 studies were included in the review. All included systematic reviews were Cochrane reviews and of good quality. The quality of randomised controlled trials (RCTs) was variable. Assessment was hampered by poor reporting of methods of randomisation, allocation concealment and blinding. Few of the non-randomised studies were of good quality. The main weakness of the economic evaluations was inappropriate use of the cost-minimisation design. The included systematic reviews reported that newer AEDs were effective as adjunctive therapy compared to placebo. For newer versus older drugs, data were available for all three monotherapy AEDs, although data for OXC and TPM were limited. There was limited, poor-quality evidence of a significant improvement in cognitive function with LTG and OXC compared with older AEDs. However, there were no consistent statistically significant differences in other clinical outcomes, including proportion of seizure-free patients. No studies assessed effectiveness of AEDs in people with intellectual disabilities or in pregnant women. There was very little evidence to assess the effectiveness of AEDs in the elderly; no significant differences were found between LTG and carbamazepine monotherapy. Sixty-seven RCTs compared adjunctive therapy with placebo, older AEDs or other newer AEDs. For newer AEDs versus placebo, a trend was observed in favour of newer drugs, and there was evidence of statistically significant differences in proportion of responders favouring newer drugs. However, it was not possible to assess long-term effectiveness. Most trials were conducted in patients with partial seizures. For newer AEDs versus older drugs, there was no evidence to assess the effectiveness of LEV, LTG or OXC, and evidence for other newer drugs was limited to single studies. Trials only included patients with partial seizures and follow-up was relatively short. There was no evidence to assess effectiveness of adjunctive LEV, OXC or TPM versus other newer drugs, and there were no time to event or cognitive data. No studies assessed the effectiveness of adjunctive AEDs in the elderly or pregnant women. There was some evidence from one study (GBP versus LTG) that both drugs have some beneficial effect on behaviour in people with learning disabilities. Eighty RCTs reported the incidence of adverse events. There was no consistent or convincing evidence to draw any conclusions concerning relative safety and tolerability of newer AEDs compared with each other, older AEDs or placebo. The integrated economic analysis for monotherapy for newly diagnosed patients with partial seizures showed that older AEDs were more likely to be cost-effective, although there was considerable uncertainty in these results. The integrated analysis suggested that newer AEDs used as adjunctive therapy for refractory patients with partial seizures were more effective and more costly than continuing with existing treatment alone. Combination therapy, involving new AEDs, may be cost-effective at a threshold willingness to pay per quality-adjusted life year (QALY) greater than 20,000 pounds, depending on patients' previous treatment history. There was, again, considerable uncertainty in these results. There were few data available to determine effectiveness of treatments for patients with generalised seizures. LTG and VPA showed similar health benefits when used as monotherapy. VPA was less costly and was likely to be cost-effective. The analysis indicated that TPM might be cost-effective when used as an adjunctive therapy, with an estimated incremental cost-effectiveness ratio of 34,500 pounds compared with continuing current treatment alone. CONCLUSIONS: There was little good-quality evidence from clinical trials to support the use of newer monotherapy or adjunctive therapy AEDs over older drugs, or to support the use of one newer AED in preference to another. In general, data relating to clinical effectiveness, safety and tolerability failed to demonstrate consistent and statistically significant differences between the drugs. The exception was comparisons between newer adjunctive AEDs and placebo, where significant differences favoured newer AEDs. However, trials often had relatively short-ter
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Common antiepileptic drugs in pregnancy in women with epilepsy
Adab, N., Smith, C. T., Vinten, J., Williamson, P. R., & Winterbottom, J. B. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004848 · Cited by 120
RetractedMethods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Self-citationEarly Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
The two‐period cross‐over clinical trial.
Hills, M., & Armitage, P. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb05903.x · Cited by 1,395
Costs, effects and C/E‐ratios alongside a clinical trial
Van Hout, B. A., Al, M. J., Gordon, G. S., & Rutten, F. F. H. (1994) · Health Economics · doi:10.1002/hec.4730030505 · Cited by 964
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.1993.03510210084032 · Cited by 944
Depression and memory impairment: A meta-analysis of the association, its pattern, and specificity.
Burt, D. B., Zembar, M. J., & Niederehe, G. (1995) · Psychological Bulletin · doi:10.1037/0033-2909.117.2.285 · Cited by 903
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
Epidemiology of the epilepsies.
Sander, J. W., & Shorvon, S. D. (1996) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.61.5.433 · Cited by 669
Martindale: The Complete Drug Reference
Mucklow, J. C. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00206.x · Cited by 639
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
Brodie, M. J., UK Lamotrigine/Carbamazepine Monotherapy Trial Group, Richens, A., & Yuen, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90581-2 · Cited by 615
Some Statistical Methods for Combining Experimental Results
Laird, N. M., & Mosteller, F. (1990) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300008916 · Cited by 568
Brodie, M. J., Overstall, P. W., & Giorgi, L. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(99)00039-x · Cited by 459
Effectiveness of First Antiepileptic Drug
Kwan, P., & Brodie, M. J. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.04501.x · Cited by 432
Briggs, A. H., Goeree, R., Blackhouse, G., & O'Brien, B. J. (2002) · Medical Decision Making · doi:10.1177/027298902400448867 · Cited by 414
Lachin, J. M., & Foulkes, M. A. (1986) · Biometrics · doi:10.2307/2531201 · Cited by 400
Mortality from epilepsy: results from a prospective population-based study
Cockerell, O. C., Hart, Y. M., Sander, J. W. A. S., Goodridge, D. M. G., Shorvon, S. D., & Johnson, A. L. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92270-5 · Cited by 398
Mogens Dam (Chairman), R. E. (1989) · Epilepsy Research · doi:10.1016/0920-1211(89)90070-3 · Cited by 393
Rzany, B., Correia, O., Kelly, J. P., Naldi, L., Auquier, A., & Stern, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05418-x · Cited by 348
Lhatoo, S. D., Johnson, A. L., Goodridge, D. M., MacDonald, B. K., Sander, J. W. A. S., & Shorvon, S. D. (2001) · Annals of Neurology · doi:10.1002/ana.70 · Cited by 342
Privitera, M., Fincham, R., Penry, J., Reife, R., Kramer, L., Pledger, G., & Karim, R. (1996) · Neurology · doi:10.1212/wnl.46.6.1678 · Cited by 339
Outcomes of Add‐on Treatment with Lamotrigine in Partial Epilepsy
Smith, D., Baker, G., Davies, G., Dewey, M., & Chadwick, D. W. (1993) · Epilepsia · doi:10.1111/j.1528-1157.1993.tb02417.x · Cited by 330
Cockerell, O. C., Johnson, A. L., Sander, J. W. A. S., & Shorvon, S. D. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01075.x · Cited by 311
Methods for the analysis of quality-of-life and survival data in health technology assessment.
Billingham, Abrams, & Jones (1999) · Health Technology Assessment · doi:10.3310/hta3100 · Cited by 307
A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures
Biton, V., Montouris, G. D., Ritter, F., Riviello, J. J., Reife, R., Lim, P., Pledger, G., & the Topiramate YTC Study Group (1999) · Neurology · doi:10.1212/wnl.52.7.1330 · Cited by 295
Faught, E., Wilder, B. J., Ramsay, R. E., Reife, R. A., Kramer, L. D., Pledger, G. W., & Karim, R. M. (1996) · Neurology · doi:10.1212/wnl.46.6.1684 · Cited by 289
On the decision rules of cost-effectiveness analysis
Johannesson, M., & Weinstein, M. C. (1993) · Journal of Health Economics · doi:10.1016/0167-6296(93)90005-y · Cited by 288
Placebo‐controlled study of the efficacy and safety of lamotrigine in patients with partial seizures
Matsuo, F., Bergen, D., Faught, E., Messenheimer, J. A., Dren, A. T., Rudd, G. D., & Lineberry, C. G. (1993) · Neurology · doi:10.1212/wnl.43.11.2284 · Cited by 280
Patients with Refractory Seizures
Devinsky, O. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905203402008 · Cited by 257
Privitera, M. D., Brodie, M. J., Mattson, R. H., Chadwick, D. W., Neto, W., Wang, S., & for the EPMN 105 Study Group (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2003.00093.x · Cited by 249
Sudden Unexplained Death in Epilepsy: Observations from a Large Clinical Development Program
Leestma, J. E., Annegers, J. F., Brodie, M. J., Brown, S., Schraeder, P., Siscovick, D., Wannamaker, B. B., Tennis, P. S., Cierpial, M. A., & Earl, N. L. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01076.x · Cited by 246
Ben‐Menachem, E., Henriksen, O., Dam, M., Mikkelsen, M., Schmidt, D., Reid, S., Reife, R., Kramer, L., Pledger, G., & Karim, R. (1996) · Epilepsia · doi:10.1111/j.1528-1157.1996.tb00606.x · Cited by 243
Cost of Epilepsy in the United States: A Model Based on Incidence and Prognosis
Begley, C. E., Annegers, J. F., Lairson, D. R., Reynolds, T. F., & Hauser, W. A. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb01794.x · Cited by 242
Guerreiro, M. M., Vigonius, U., Pohlmann, H., de Manreza, M. L. G., Fejerman, N., Antoniuk, S. A., & Moore, A. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(97)00025-9 · Cited by 241
Elterman, R. D., Glauser, T. A., Wyllie, E., Reife, R., Wu, S.-C., Pledger, G., & the Topiramate YP Study Group (1999) · Neurology · doi:10.1212/wnl.52.7.1338 · Cited by 235
Steiner, T. J., Dellaportas, C. I., Findley, L. J., Gross, M., Gibberd, F. B., Perkin, G. D., Park, D. M., & Abbott, R. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb05562.x · Cited by 234
Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy
Biton, V., Mirza, W., Montouris, G., Vuong, A., Hammer, A. E., & Barrett, P. S. (2001) · Neurology · doi:10.1212/wnl.56.2.172 · Cited by 234
Betts, T., Waegemans, T., & Crawford, P. (2000) · Seizure · doi:10.1053/seiz.2000.0380 · Cited by 230
Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy
(2000) · Epilepsia · doi:10.1111/j.1499-1654.2000.001597.x · Cited by 225
Messenheimer, J., Ramsay, R. E., Willmore, L. J., Leroy, R. F., Zielinski, J., Mattson, R., Pellock, J. M., Valakas, A. M., Womble, G., & Risner, M. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb02920.x · Cited by 217
Christe, W., Krämer, G., Vigonius, U., Pohlmann, H., Steinhoff, B. J., Brodie, M. J., & Moore, A. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(96)01013-3 · Cited by 216
Bill, P. A., Vigonius, U., Pohlmann, H., Guerreiro, C. A. M., Kochen, S., Saffer, D., & Moore, A. (1997) · Epilepsy Research · doi:10.1016/s0920-1211(97)00024-7 · Cited by 216
Gabapentin in partial epilepsy
Uk Gabapentin Study Group (1990) · The Lancet · doi:10.1016/0140-6736(90)91123-r · Cited by 209
Uptake and Costs of Care for Epilepsy: Findings from a U.K. Regional Study
Jacoby, A., Buck, D., Baker, G., McNamee, P., Graham‐Jones, S., & Chadwick, D. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01164.x · Cited by 208
A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures
Chadwick, D. W., Anhut, H., Greiner, M. J., Alexander, J., Murray, G. H., Garofalo, E. A., Pierce, M. W., & The International Gabapentin Monotherapy Study Group 945-77 (1998) · Neurology · doi:10.1212/wnl.51.5.1282 · Cited by 205
A systematic review of the safety profile of levetiracetam: a new antiepileptic drug
French, J., Edrich, P., & Cramer, J. A. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00296-0 · Cited by 198
Aldenkamp, A. P., Baker, G., Mulder, O. G., Chadwick, D., Cooper, P., Doelman, J., Duncan, R., Gassmann‐Mayer, C., de Haan, G. J., Hughson, C., et al. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00322.x · Cited by 197
Cockerell, O. C., Hart, Y. M., Sander, J. W. A. S., & Shorvon, S. D. (1994) · Epilepsy Research · doi:10.1016/0920-1211(94)90045-0 · Cited by 191
Heaney, D. C., MacDonald, B. K., Everitt, A., Stevenson, S., Leonardi, G. S., Wilkinson, P., & Sander, J. W. (2002) · BMJ · doi:10.1136/bmj.325.7371.1013 · Cited by 191
Anhut, H., Ashman, P., Feuerstein, T. J., Sauermann, W., Saunders, M., Schmidt, B., & The International Gabapentin Study Group (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb02513.x · Cited by 190
Tassinari, C. A., Michelucci, R., Chauvel, P., Chodkiewicz, J., Shorvon, S., Henriksen, O., Dam, M., Reife, R., Pledger, G., & Karim, R. (1996) · Epilepsia · doi:10.1111/j.1528-1157.1996.tb00649.x · Cited by 190
Kälviäinen, R. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540340081016 · Cited by 174
Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy
Binnie, C. D., Debets, R. M. C., Engelsman, M., Meijer, J. W. A., Meinardi, H., Overweg, J., Peck, A. W., Van Wieringen, A., & Yuen, W. C. (1989) · Epilepsy Research · doi:10.1016/0920-1211(89)90007-7 · Cited by 169
Spectrum of Activity of Lamotrigine in Treatment-Refractory Bipolar Disorder
Calabrese, J. R., Bowden, C. L., McElroy, S. L., Cookson, J., Andersen, J., Keck, Jr., Rhodes, L., Bolden-Watson, C., Zhou, J., & Ascher, J. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1019 · Cited by 167
Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy
Sharief, M., Viteri, C., Ben-Menachem, E., Weber, M., Reife, R., Pledger, G., & Karim, R. (1996) · Epilepsy Research · doi:10.1016/s0920-1211(96)00029-0 · Cited by 167
Loiseau, P., Yuen, A. W. C., Duché, B., Ménager, T., & Arné-Bès, M. C. (1990) · Epilepsy Research · doi:10.1016/0920-1211(90)90099-h · Cited by 163
Schapel, G. J., Beran, R. G., Vajda, F. J. E., Berkovic, S. F., Mashford, M. L., Dunagan, F. M., Yuen, W. C., & Davies, G. (1993) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.5.448 · Cited by 150
Meta-analyses involving cross-over trials: methodological issues
Stedman, M. R., Curtin, F., Elbourne, D. R., Kesselheim, A. S., & Brookhart, M. A. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp345 · Cited by 148
Reunanen, M., Dam, M., & Yuen, A. W. C. (1996) · Epilepsy Research · doi:10.1016/0920-1211(95)00085-2 · Cited by 147
Safety of Long‐Term Lamotrigine in Epilepsy
Mackay, F. J., Wilton, L., Peace, G. L., Freemantle, S. N., & Mann, R. D. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01252.x · Cited by 145
The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England
Wilton, L., Pearce, G. L., Martin, R. M., Mackay, F. J., & Mann, R. D. (1998) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1998.tb10234.x · Cited by 141
French, J. A., Mosier, M. C., Walker, S., et al. (1996) · Neurology · doi:10.1212/wnl.46.1.54 · Cited by 134
Effect of Levetiracetam on Epilepsy‐Related Quality of Life
Cramer, J. A., Arrigo, C., Hammée, G. V., Gauer, L. J., Cereghino, J. J., & for the N132 Study Group (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00255.x · Cited by 132
Ades, A. E. (2003) · Statistics in Medicine · doi:10.1002/sim.1566 · Cited by 131
Factors Influencing the Incidence of Lamotrigine-Related Skin Rash
Wong, I. C. K., Mawer, G. E., & Sander, J. W. A. S. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18422 · Cited by 130
Leach, J. P., Girvan, J., Paul, A., & Brodie, M. J. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.4.372 · Cited by 129
Reporting of adverse drug reactions in randomised controlled trials – a systematic survey
Loke, Y. K., & Derry, S. (2001) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-1-3 · Cited by 128
Long-term continuation of levetiracetam in patients with refractory epilepsy
Krakow, K., Walker, M. C., Otoul, C., & Sander, J. W. A. S. (2001) · Neurology · doi:10.1212/wnl.56.12.1772 · Cited by 128
A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children
DUCHOWNY, M. S., Pellock, J. M., Graf, W. D., Billard, C., Gilman, J. T., Casale, E. J., Womble, G. P., Risner, M. E., Manasco, P. K., & for the Lamictal Pediatric Partial Seizure Study Group (1999) · Neurology · doi:10.1212/wnl.53.8.1724 · Cited by 126
Estimating CE Ratios under Second-order Uncertainty
Stinnett, A. A., & Paltiel, A. D. (1997) · Medical Decision Making · doi:10.1177/0272989x9701700414 · Cited by 124
Quality of Life in Patients with Epilepsy and Impact of Treatments
Berto, P. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220150-00002 · Cited by 116
Prescription‐event monitoring—recent progress and future horizons
Mann, R. D. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00774.x · Cited by 114
Vigabatrin Visual Toxicity: Evolution and Dose Dependence
Malmgren, K., Ben‐Menachem, E., & Frisén, L. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.28600.x · Cited by 114
Derry, S., Loke, Y. K., & Aronson, J. K. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-7 · Cited by 112
Gabapentin versus Lamotrigine Monotherapy: A Double‐blind Comparison in Newly Diagnosed Epilepsy
Brodie, M. J., Chadwick, D. W., Anhut, H., Otte, A., Messmer, S., Maton, S., Sauermann, W., Murray, G., Garofalo, E. A., & for the Gabapentin Study Group 945‐212 (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.45401.x · Cited by 110
Double‐Blind, Placebo‐Controlled, Lamotrigine in Treatment‐Resistant Generalised Epilepsy
Beran, R. G., Berkovic, S. F., Dunagan, F. M., Vajda, F. J. E., Danta, G., Black, A. B., & Mackenzie, R. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01332.x · Cited by 107
Long‐Term Retention Rates of Lamotrigine, Gabapentin, and Topiramate in Chronic Epilepsy
Lhatoo, S. D., Wong, I. C. K., Polizzi, G., & Sander, J. W. A. S. (2000) · Epilepsia · doi:10.1111/j.1499-1654.2000.001592.x · Cited by 104
Betts, T., Goodwin, G. M., & WITHERS, R. M. (1991) · Epilepsia · doi:10.1111/j.1528-1157.1991.tb05881.x · Cited by 103
Ben‐Menachem, E., & Gilland, E. (2002) · Seizure · doi:10.1016/s1059-1311(02)00251-0 · Cited by 101
Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy
Dodrill, C. B., Arnett, J. L., Sommerville, K. W., et al. (1997) · Neurology · doi:10.1212/wnl.48.4.1025 · Cited by 101
A Pilot Trial of Adjunctive Gabapentin in the Treatment of Bipolar Disorder
McElroy, S. L., Soutullo, C. A., Keck, P. E., & Kmetz, G. F. (1997) · Annals of Clinical Psychiatry · doi:10.1023/a:1026257303275 · Cited by 99
Marson, A. G., Hutton, J. L., Leach, J. P., Castillo, S., Schmidt, D., White, S. J., Chaisewikul, R., Privitera, M., & Chadwick, D. W. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00287-x · Cited by 99
Adjunctive treatment of partial seizures with tiagabine: A placebo-controlled trial
Richens, A., Chadwick, D. W., Duncan, J. S., et al. (1995) · Epilepsy Research · doi:10.1016/0920-1211(95)00006-v · Cited by 98
Assessment of therapeutic safety in systematic reviews: literature review
Ernst, E., & Pittler, M. H. (2001) · BMJ · doi:10.1136/bmj.323.7312.546 · Cited by 97
Reporting of safety data from randomised trials
Ioannidis, J. P. A., & Contopoulos‐Ioannidis, D. G. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79825-1 · Cited by 97
Dose–response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy
Boon, P., Chauvel, P., Pohlmann‐Eden, B., Otoul, C., & Wroe, S. J. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(01)00323-0 · Cited by 95
Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation
Cramer, J. A., Menachem, E. B., & French, J. A. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00286-8 · Cited by 93
Dodrill, C. B., Arnett, J. L., Sommerville, K. W., & Sussman, N. M. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb00976.x · Cited by 91
Low-dose topiramate in adults with treatment-resistant partial-onset seizures
Guberman, A. H., Neto, W., Gassmann-Mayer, C., & the EPAJ-119 Study Group (2002) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2002.02071.x · Cited by 89
Adding Lamotrigine to Valproate: Incidence of Rash and Other Adverse Effects
Faught, E., Morris, G. L., Jacobson, M. P., et al. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00831.x · Cited by 89
Established antiepileptic drugs
Brodie, M. J., & Dichter, M. A. (1997) · Seizure · doi:10.1016/s1059-1311(97)80001-5 · Cited by 86
Bergey, G. K., Morris, H. H., Rosenfeld, W. E., Blume, W. T., Penovich, P. E., Morrell, M. J., Leiderman, D. B., Crockatt, J. G., LaMoreaux, L., Garofalo, E., et al. (1997) · Neurology · doi:10.1212/wnl.49.3.739 · Cited by 86
Edwards, K. R., Sackellares, J. C., Vuong, A., Hammer, A. E., & Barrett, P. S. (2001) · Epilepsy & Behavior · doi:10.1006/ebeh.2000.0143 · Cited by 85
Scientific and Ethical Issues in Equivalence Trials
Djulbegović, B. (2001) · JAMA · doi:10.1001/jama.285.9.1206 · Cited by 79
Safety and Tolerability of Gabapentin as Adjunctive Therapy in a Large, Multicenter Study
McLean, M. J., Morrell, M. J., Willmore, L. J., Privitera, M., Faught, E., Holmes, G. L., Magnus‐Miller, L., Bernstein, P., & Rose‐Legatt, A. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00804.x · Cited by 79
Oxcarbazepine-induced hyponatremia, a cross-sectional study
Nielsen, O. A., Johannessen, A. C., & Bardrum, B. (1988) · Epilepsy Research · doi:10.1016/0920-1211(88)90018-6 · Cited by 78
Seizure Severity and the Quality of Life
Smith, D. F., Chadwick, D. W., Baker, G. A., Davis, G., & Dewey, M. E. (1993) · Epilepsia · doi:10.1111/j.1528-1157.1993.tb05921.x · Cited by 76
Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy
Brodie, M. J., & Mumford, J. P. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(98)00110-7 · Cited by 74
International Experience with Tiagabine Add‐On Therapy
Ben‐Menachem, E. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb06010.x · Cited by 71
The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy
Sander, J. W. A. S., Trevisol-Bittencourt, P. C., Hart, Y. M., Patsalos, P. N., & Shorvon, S. D. (1990) · Epilepsy Research · doi:10.1016/0920-1211(90)90019-r · Cited by 68
Yen, D., Yu, H., Guo, Y., Chen, C., Yiu, C., & Su, M. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00321.x · Cited by 68
Properties of the 15D and EQ-5D utility measures in a community sample of people with epilepsy
Stavem, K., Bjørnæs, H., & Lossius, M. I. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00201-7 · Cited by 65
Topiramate - Safety and Tolerability
Jones, M. W. (1998) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100034855 · Cited by 65
Effects of vigabatrin on partial seizures and cognitive function.
Grünewald, R. A., Thompson, P. J., Corcoran, R., et al. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.9.1057 · Cited by 62
Vigabatrin: rational treatment for chronic epilepsy.
RING, H. A., Heller, A., Farr, I., & Reynolds, E. H. (1990) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.12.1051 · Cited by 57
Kaminow, L., Schimschock, J. R., Hammer, A. E., & Vuong, A. (2003) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.08.033 · Cited by 56
Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania
Knoll, J. L., Stegman, K., & Suppes, T. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00027-5 · Cited by 56
Lindberger, M., Ålenius, M., Frisén, L., Johannessen, S. I., Larsson, S., Malmgren, K., & Torason, T. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb04607.x · Cited by 55
Beydoun, A. A., Fakhoury, T. A., Nasreddine, W., & Abou‐Khalil, B. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01357.x · Cited by 54
Baker, G. A., Hesdon, B., & Marson, A. G. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00110.x · Cited by 52
Rapid initiation of gabapentin
Fisher, R. S., Sachdeo, R. C., Pellock, J. M., Penovich, P. E., Magnus, L., & Bernstein, P. (2001) · Neurology · doi:10.1212/wnl.56.6.743 · Cited by 52
Heaney, D. C., Shorvon, S. D., & Sander, J. W. A. S. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb05117.x · Cited by 51
Wong, I. C. K., Mawer, G. E., & Sander, J. W. A. S. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.254001.x · Cited by 49
Clinical experience of marketed Levetiracetam in an epilepsy clinic—a one year follow up study
Betts, T., YARROW, H., Greenhill, L., & BARRETT, M. (2003) · Seizure · doi:10.1016/s1059-1311(02)00258-3 · Cited by 48
Crawford, P. M., Brown, S., & Kerr, M. (2001) · Seizure · doi:10.1053/seiz.2000.0474 · Cited by 48
Baulac, M. (1998) · Seizure · doi:10.1016/s1059-1311(98)90009-7 · Cited by 45
Active-control equivalence trials and antihypertensive agents
McAlister, F. A., & Sackett, D. L. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00900-7 · Cited by 45
Proof of efficacy trials: cross-over versus parallel-group
Richens, A. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00214-5 · Cited by 45
Comaish, I. F., Gorman, C., Brimlow, G., Barber, C., Orr, G. M., & Galloway, N. R. (2002) · Documenta Ophthalmologica · doi:10.1023/a:1014603229383 · Cited by 44
Beydoun, A. A., Sachdeo, R. C., Kutluay, E., McCague, K., & D’Souza, J. (2003) · Epilepsia · doi:10.1046/j.1528-1157.2003.54102.x · Cited by 41
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Efficacy of gabapentin as adjunctive therapy in a large, multicenter study
Morrell, M. J., McLean, M. J., Willmore, L. J., et al. (2000) · Seizure · doi:10.1053/seiz.2000.0407 · Cited by 38
Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy
Cocito, L., Maffini, M., & Loeb, C. (1994) · Epilepsy Research · doi:10.1016/0920-1211(94)90022-1 · Cited by 36
Lamotrigine: A six-month, placebo-controlled, safety and tolerance study
Schachter, S. C., Leppik, I. E., Matsuo, F., Messenheimer, J. A., Faught, E., Moore, E. L., & Risner, M. E. (1995) · Journal of Epilepsy · doi:10.1016/0896-6974(95)00034-b · Cited by 34
Schaffer, C. B., & Schaffer, L. C. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00198-0 · Cited by 34
The contribution of the measurement of seizure severity to quality of life research
Smith, D., Baker, G. A., Jacoby, A., & Chadwick, D. W. (1995) · Quality of Life Research · doi:10.1007/bf01833608 · Cited by 31
Beran, R. G., Berkovic, S. F., Buchanan, N., et al. (1996) · Seizure · doi:10.1016/s1059-1311(96)80018-5 · Cited by 30
Matsuo, F., Gay, P. E., Madsen, J. A., Tolman, K. G., Rollins, D. E., Risner, M. E., & Lai, A. A. (1996) · Epilepsia · doi:10.1111/j.1528-1157.1996.tb00038.x · Cited by 28
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options
O'Neill, B. A., Trimble, M., & Bloom, D. S. (1995) · Seizure · doi:10.1016/s1059-1311(05)80076-7 · Cited by 24
Baker, G. A., Currie, N. G. T., Light, M., & Schneiderman, J. (2002) · Seizure · doi:10.1053/seiz.2001.0581 · Cited by 22
Lamotrigine versus carbamazepine in epilepsy
O’Donoghue, M., Sander, J. W. A. S., Eeg‐Olofsson, O., Reynolds, E. H., Brodie, M. J., Richens, A., Yuen, A. W. C., Duval, X., Chosidow, O., Semah, F., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90945-1 · Cited by 19
The Short‐Term Impact of Adjunctive Tiagabine on Health‐Related Quality of Life
Cramer, J. A., Ryan, J., Chang, J. R., Sommerville, K. W., & the M92‐825 Study Group (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.01018.x · Cited by 15
Impact of lamotrigine on patients with refractory epilepsy: the Leicester experience
Martin, P. J., & Millac, P. A. H. (1994) · Seizure · doi:10.1016/s1059-1311(05)80190-6 · Cited by 7
Gabapentin and the Prophylaxis of Bipolar Disorders in Patients Intolerant to Lithium
Mauri, M. C., Laini, V., Scalvini, M. E., Omboni, A. C., Ferrari, V. M. S., Clemente, A., Salvi, V., & Cerveri, G. (2001) · Clinical Drug Investigation · doi:10.2165/00044011-200121030-00002 · Cited by 3
Sperfeld (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199911)46:5 · Cited by 2
Schreiner, A., Wheless, J. W., & Wang, S. (2004) · Neuropediatrics · doi:10.1055/s-2004-819390 · Cited by 1
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Systematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
Metadata
- Authors
- Wilby, J., Kainth, A., Hawkins, N., Epstein, D., McIntosh, H., McDaid, C., Mason, A., Golder, S., O'Meara, S., Sculpher, M., Drummond, M., & Forbes, C.
- Venue
- Health Technology Assessment
- Published
- 2005-04
- Volume
- 9
- Issue
- 15
- Pages
- 1-157, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2111106069
- Cited by
- 271
- References
- 138
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.